Shots:

• The EC approval is based on four P-III ultIMMa-1- ultIMMa-2- IMMvent & IMMhance assessing Skyrizi (risankizumab) vs PBO- adalimumab- ustekinumab in 2000+ adult patients with moderate to severe plaque psoriasis
• The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%- 84% & 75%); Skyrizi vs adalimumab- PASI 90 (72% vs 47%); switched patients vs continued adalimumab- PASI 90 (66% vs 21%); @16wks. & 52wks. met its co-1EPs; Skyrizi vs ustekinumab- (DLQI) score (75% & 71% vs 47% & 44%)
• Skyrizi (risankizumab) is a humanized immunoglobulin mAb- inhibits IL-23 by binding to its p19 subunit and has received MHLW’s approval for multiple plaque psoriasis conditions in Mar’19 & Health Canada and the US FDA approval for moderate to severe plaque psoriasis in Apr’19

Ref: AbbVie | Image:AbbVie